These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 21720399)
1. Timing of patent filing and market exclusivity. Dunn MK Nat Rev Drug Discov; 2011 Jul; 10(7):487-8. PubMed ID: 21720399 [No Abstract] [Full Text] [Related]
2. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity. Fernandez DS; Huie JT Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155 [No Abstract] [Full Text] [Related]
3. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification. Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950 [TBL] [Abstract][Full Text] [Related]
4. Fifty years of drug amendments revisited: in easy-to-swallow capsule form. Kaplan AH Food Drug Law J; 1995; 50 Spec():179-96. PubMed ID: 10343042 [No Abstract] [Full Text] [Related]
5. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
6. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
7. The problem of new uses. Eisenberg RS Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897 [No Abstract] [Full Text] [Related]
8. A new history and discussion of 180-day exclusivity. Korn DE; Lietzan E; Scott SW Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288 [TBL] [Abstract][Full Text] [Related]
9. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Orlando VI Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734 [No Abstract] [Full Text] [Related]
10. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
11. Encouraging guidance released for biosimilar manufacturers. Reinke T Manag Care; 2014 Aug; 23(8):10, 13. PubMed ID: 25225711 [No Abstract] [Full Text] [Related]
13. A cheat sheet to navigate the complex maze of exclusivities in the United States. Peng B; Tomas MC Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306 [No Abstract] [Full Text] [Related]
14. FDA's role in making exclusivity determinations. Dickinson EH Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573 [No Abstract] [Full Text] [Related]
15. Issues in the interpretation of 180-day exclusivity. Lietzan E; Korn DE Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026 [No Abstract] [Full Text] [Related]
16. Patent infringement. Generic HIV drugmaker's patent claim is time-barred. AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916 [No Abstract] [Full Text] [Related]
17. Market exclusivity for biologics. Wheadon DE N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494 [No Abstract] [Full Text] [Related]
18. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
19. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
20. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]